| Literature DB >> 23326665 |
Giuseppe Caminiti1, Francesca Ranghi, Sara De Benedetti, Daniela Battaglia, Arianna Arisi, Alessio Franchini, Fabiana Facchini, Veronica Cioffi, Maurizio Volterrani.
Abstract
Purpose. To determine whether the presence of cognitive impairment (CI) affects physical recovery of patients with chronic heart failure (CHF) undergoing a cardiac rehabilitation program (CRP). Methods. We enrolled 80 CHF patients (M/F = 53/27). CI was evaluated by means of the Mini-Mental State Examination (MMSE), exercise tolerance was evaluated by six-minute walking test (6 mwt). All patients underwent a 6-week CRP program at 50-70% of maximal V(O2). Patients were divided into two groups according to their MMSE (group 1: 16-23; group 2: 24-30). Results. MMSE resulted directly related to ejection fraction (r = 0.42; P = 0.03), and it was inversely related to creatinine (r = -0.36; P = 0.04). At 6 week group 1 had a lower increase in distance walked at 6 MWT than group 2 (P = 0.008). At multivariate logistic regression MMSE 16-23 predicted a reduced exercise recovery in the overall population (OR = 1.84; 95% CI = 1.50-2.18) and in women (OR = 1.42; 95% CI = 1.22-1.75), while it was not predicted in males. Conclusions. CI is a marker of advanced CHF and is an independent predictor of lower exercise recovery after CRP.Entities:
Year: 2012 PMID: 23326665 PMCID: PMC3544314 DOI: 10.1155/2012/218928
Source DB: PubMed Journal: Rehabil Res Pract ISSN: 2090-2867
Statistical comparison among baseline variables of subjects of group 1 and group 2.
| Group 1 | Group 2 | |
|---|---|---|
| (MMSE 16–23) | (MMSE 24–30) | |
|
|
| |
| Age, y | 73.5 ± 13 | 70.7 ± 11* |
| M/F | 29/14 | 24/13 |
| BMI (kg/m2) | 27 ± 8 | 26 ± 4 |
| NYHA class | 2.7 ± 0.5 | 2.2 ± 0.4* |
| Resting HR, bpm | 88 ± 7 | 76 ± 7* |
| Systolic BP, mmHg | 108 ± 19 | 107 ± 21 |
| Diastolic BP, mmHg | 82 ± 10 | 80 ± 14 |
| Echography | ||
| LVEF | 27.4 ± 7 | 34.9 ± 6* |
| LVDD | 63.1 ± 11 | 62.6 ± 8 |
| E/A | 1.4 ± 0.7 | 1.4 ± 0.8 |
| E deceleration time | 171 ± 23 | 180 ± 17 |
| Laboratory tests | ||
| NT proBNP, pg/mL | 302.7 ± 51 | 223.4 ± 34* |
| Creatinine, mg/dL | 1.9 ± 0.3 | 1.4 ± 0.5* |
| GFR, mL/min | 34.9 ± 9 | 50.1 ± 7* |
| Haemoglobin, g/dL | 10.4 ± 3 | 11.1 ± 4 |
| Comorbidities | ||
| Hypertension | 29 (67) | 24 (65) |
| Diabetes | 21 (48) | 12 (32)* |
| Dislipidemia | 17 (39) | 15 (40) |
| COPD | 16 (37) | 11 (30) |
| Atrial fibrillation | 15 (35) | 10 (27)* |
| Therapy | ||
| Beta-blockers | 36 (84) | 30 (81) |
| ACE-i/ARBs | 39 (91) | 36 (97) |
| Diuretics | 34 (79) | 27 (73) |
| Digoxin | 9 (21) | 6 (28) |
*Intergroup differences P < 0.05.
GFR: glomerular filtration rate.
LVDD: left ventricular diastolic diameter.
LVEF: left ventricular ejection fraction.
Logistic regression analysis evaluating the independent predictor power of CI (MMSE < 24) in the overall population, and according to gender.
| MMSE 16–23 | Odds ratio |
|
|---|---|---|
| Overall population | ||
| Unadjusted model | 2.21 (1.62–2.55) | <0.001 |
| Adjusted model | 1.84 (1.50–2.18) | 0.024 |
| Males | ||
| Unadjusted model | 1.5 (0.98–1.91) | 0.036 |
| Adjusted model | 1.20 (0.87–1.52) | 0.354 |
| Females | ||
| Unadjusted model | 1.76 (1.30–2.07) | 0.031 |
| Adjusted model | 1.42 (1.22–1.75) | 0.047 |
Adjusted for LV ejection fraction, diabetes, age, atrial fibrillation, creatinine, and haemoglobin.